Aktienanalyse zu Fate Therapeutics Inc (FATE)FATEFate Therapeutics Inc

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. The Company's pipeline includes iPSC-derived, chimeric antigen receptor (CAR)-targeted T-cell and NK cell product candidates. The iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. The Company's product candidates under development include FT819, FT522, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT825 is its first iPSC-derived CAR T-cell product candidate for the treatment of solid tumors being developed in collaboration with Ono Pharmaceutical. FT836 is the Company's multiplexed-engineered CAR T-cell product candidate targeting MHC proteins MICA and MICB. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Fate Therapeutics Inc is a good buy right now due to its current price of $2.01, which is significantly below the analyst price target of $4, suggesting a potential upside of 99.5%. Additionally, the stock has shown a year-to-date change of +103.77%, indicating strong momentum. However, investors should be cautious of the negative net income trend, with the latest reported figure at -31,590,000 USD for Q2 2026, which highlights ongoing financial challenges.

6 analysts cover FATE: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 4.64.